Versor Investments LP Invests $676,000 in Artivion, Inc. $AORT

Versor Investments LP bought a new position in shares of Artivion, Inc. (NYSE:AORT) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 15,962 shares of the company’s stock, valued at approximately $676,000.

Several other hedge funds have also modified their holdings of AORT. Invesco Ltd. boosted its position in shares of Artivion by 40.8% in the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after purchasing an additional 139,370 shares during the period. Osterweis Capital Management Inc. purchased a new stake in Artivion during the second quarter valued at about $3,750,000. Bank of America Corp DE boosted its holdings in shares of Artivion by 22.8% in the second quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock worth $20,062,000 after buying an additional 119,634 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Artivion in the second quarter worth about $2,582,000. Finally, Bridger Management LLC increased its position in shares of Artivion by 106.2% in the second quarter. Bridger Management LLC now owns 132,588 shares of the company’s stock worth $4,123,000 after acquiring an additional 68,288 shares in the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Jean F. Holloway sold 7,315 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $45.30, for a total value of $331,369.50. Following the completion of the sale, the senior vice president owned 156,093 shares of the company’s stock, valued at approximately $7,071,012.90. The trade was a 4.48% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Amy Horton sold 4,572 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $44.42, for a total value of $203,088.24. Following the completion of the transaction, the chief accounting officer owned 130,058 shares in the company, valued at $5,777,176.36. This represents a 3.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 141,234 shares of company stock valued at $6,366,621. 7.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Citizens Jmp upped their price target on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Oppenheimer reissued an “outperform” rating and set a $50.00 target price on shares of Artivion in a research note on Friday, November 7th. Canaccord Genuity Group restated a “buy” rating and issued a $51.00 target price on shares of Artivion in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded Artivion from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 24th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $49.11.

Artivion Trading Down 0.8%

Shares of NYSE:AORT opened at $40.04 on Thursday. The firm has a fifty day moving average of $43.86 and a two-hundred day moving average of $42.77. The firm has a market capitalization of $1.90 billion, a P/E ratio of -166.81 and a beta of 1.59. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $48.25. The company has a quick ratio of 2.88, a current ratio of 3.93 and a debt-to-equity ratio of 0.50.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.